Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Atea Pharmaceuticals Inc stock

Learn how to easily invest in Atea Pharmaceuticals Inc stock.

Atea Pharmaceuticals Inc is a biotechnology business based in the US. Atea Pharmaceuticals Inc shares (AVIR) are listed on the NASDAQ and all prices are listed in US Dollars. Atea Pharmaceuticals Inc employs 56 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Atea Pharmaceuticals Inc

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AVIR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Atea Pharmaceuticals Inc stock price (NASDAQ: AVIR)

Use our graph to track the performance of AVIR stocks over time.

Atea Pharmaceuticals Inc shares at a glance

Information last updated 2022-01-11.
Latest market close$7.30
52-week range$7.24 - $94.17
50-day moving average $9.11
200-day moving average $24.46
Wall St. target price$9.00
PE ratio 25.2885
Dividend yield N/A (0%)
Earnings per share (TTM) $0.31

Buy Atea Pharmaceuticals Inc shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
SoFi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
Stocks, Options, ETFs
$0
$0 per year
Get a free stock valued up to $3500
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
$125 - $625
Open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Atea Pharmaceuticals Inc stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Atea Pharmaceuticals Inc price performance over time

Historical closes compared with the close of $7.3 from 2022-01-14

1 week (2022-01-10) -4.95%
1 month (2021-12-17) -14.62%
3 months (2021-10-15) -81.42%
6 months (2021-07-16) -68.12%
1 year (2021-01-15) -86.34%
2 years (2020-01-13) N/A
3 years (2019-01-13) N/A
5 years (2017-01-13) N/A

Is Atea Pharmaceuticals Inc stock undervalued or overvalued?

Valuing Atea Pharmaceuticals Inc stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Atea Pharmaceuticals Inc's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Atea Pharmaceuticals Inc's P/E ratio

Atea Pharmaceuticals Inc's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 25x. In other words, Atea Pharmaceuticals Inc shares trade at around 25x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, Atea Pharmaceuticals Inc's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

Atea Pharmaceuticals Inc's EBITDA

Atea Pharmaceuticals Inc's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $37.9 million.

The EBITDA is a measure of a Atea Pharmaceuticals Inc's overall financial performance and is widely used to measure a its profitability.

To put Atea Pharmaceuticals Inc's EBITDA into context you can compare it against that of similar companies.

Atea Pharmaceuticals Inc financials

Revenue TTM $207.8 million
Operating margin TTM 18.21%
Gross profit TTM $10.6 million
Return on assets TTM 4.96%
Return on equity TTM 7.26%
Profit margin 11.89%
Book value $7.00
Market capitalisation $655.7 million

TTM: trailing 12 months

Atea Pharmaceuticals Inc share dividends

We're not expecting Atea Pharmaceuticals Inc to pay a dividend over the next 12 months.

You may also wish to consider:

Atea Pharmaceuticals Inc overview

Atea Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in Phase I/IIa clinical trial for the treatment of chronic hepatitis C; and AT-889, an investigational, second-generation nucleoside pyrimidine prodrug and other compounds for the treatment of respiratory syncytial virus. It has a Roche License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. for development and commercialization related to AT-527 outside of the United States.

Frequently asked questions

What percentage of Atea Pharmaceuticals Inc is owned by insiders or institutions?
Currently 18.427% of Atea Pharmaceuticals Inc shares are held by insiders and 75.971% by institutions.
How many people work for Atea Pharmaceuticals Inc?
Latest data suggests 56 work at Atea Pharmaceuticals Inc.
When does the fiscal year end for Atea Pharmaceuticals Inc?
Atea Pharmaceuticals Inc's fiscal year ends in December.
Where is Atea Pharmaceuticals Inc based?
Atea Pharmaceuticals Inc's address is: 125 Summer Street, Boston, MA, United States, 02110
What is Atea Pharmaceuticals Inc's ISIN number?
Atea Pharmaceuticals Inc's international securities identification number is: US04683R1068

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site